These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 11969409)

  • 1. Prime site binding inhibitors of a serine protease: NS3/4A of hepatitis C virus.
    Ingallinella P; Fattori D; Altamura S; Steinkühler C; Koch U; Cicero D; Bazzo R; Cortese R; Bianchi E; Pessi A
    Biochemistry; 2002 Apr; 41(17):5483-92. PubMed ID: 11969409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimization of the P'-region of peptide inhibitors of hepatitis C virus NS3/4A protease.
    Ingallinella P; Bianchi E; Ingenito R; Koch U; Steinkühler C; Altamura S; Pessi A
    Biochemistry; 2000 Oct; 39(42):12898-906. PubMed ID: 11041854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evolution, synthesis and SAR of tripeptide alpha-ketoacid inhibitors of the hepatitis C virus NS3/NS4A serine protease.
    Colarusso S; Gerlach B; Koch U; Muraglia E; Conte I; Stansfield I; Matassa VG; Narjes F
    Bioorg Med Chem Lett; 2002 Feb; 12(4):705-8. PubMed ID: 11844706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of prime-site occupancy on the hepatitis C virus NS3 protease structure.
    Casbarra A; Piaz FD; Ingallinella P; Orrù S; Pucci P; Pessi A; Bianchi E
    Protein Sci; 2002 Sep; 11(9):2102-12. PubMed ID: 12192066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of small-molecule inhibitors of HCV NS3-4A protease as potential therapeutic agents against HCV infection.
    Chen SH; Tan SL
    Curr Med Chem; 2005; 12(20):2317-42. PubMed ID: 16181135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enzymatic characterization of membrane-associated hepatitis C virus NS3-4A heterocomplex serine protease activity expressed in human cells.
    Hamill P; Jean F
    Biochemistry; 2005 May; 44(17):6586-96. PubMed ID: 15850392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitors of hepatitis C virus NS3/4A: alpha-ketoamide based macrocyclic inhibitors.
    Avolio S; Robertson K; Hernando JI; DiMuzio J; Summa V
    Bioorg Med Chem Lett; 2009 Apr; 19(8):2295-8. PubMed ID: 19285390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conformational changes in human hepatitis C virus NS3 protease upon binding of product-based inhibitors.
    Bianchi E; Orrù S; Dal Piaz F; Ingenito R; Casbarra A; Biasiol G; Koch U; Pucci P; Pessi A
    Biochemistry; 1999 Oct; 38(42):13844-52. PubMed ID: 10529230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and synthesis of ethyl pyrrolidine-5,5-trans-lactams as inhibitors of hepatitis C virus NS3/4A protease.
    Slater MJ; Andrews DM; Baker G; Bethell SS; Carey S; Chaignot H; Clarke B; Coomber B; Ellis M; Good A; Gray N; Hardy G; Jones P; Mills G; Robinson E
    Bioorg Med Chem Lett; 2002 Dec; 12(23):3359-62. PubMed ID: 12419361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibitor binding induces active site stabilization of the HCV NS3 protein serine protease domain.
    Barbato G; Cicero DO; Cordier F; Narjes F; Gerlach B; Sambucini S; Grzesiek S; Matassa VG; De Francesco R; Bazzo R
    EMBO J; 2000 Mar; 19(6):1195-206. PubMed ID: 10716920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of the HCV NS3/4A protease inhibitor (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3- [2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (Sch 503034) II. Key steps in structure-based optimization.
    Prongay AJ; Guo Z; Yao N; Pichardo J; Fischmann T; Strickland C; Myers J; Weber PC; Beyer BM; Ingram R; Hong Z; Prosise WW; Ramanathan L; Taremi SS; Yarosh-Tomaine T; Zhang R; Senior M; Yang RS; Malcolm B; Arasappan A; Bennett F; Bogen SL; Chen K; Jao E; Liu YT; Lovey RG; Saksena AK; Venkatraman S; Girijavallabhan V; Njoroge FG; Madison V
    J Med Chem; 2007 May; 50(10):2310-8. PubMed ID: 17444623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The design and synthesis of potent inhibitors of hepatitis C virus NS3-4A proteinase.
    Attwood MR; Bennett JM; Campbell AD; Canning GG; Carr MG; Conway E; Dunsdon RM; Greening JR; Jones PS; Kay PB; Handa BK; Hurst DN; Jennings NS; Jordan S; Keech E; O'Brien MA; Overton HA; King-Underwood J; Raynham TM; Stenson KP; Wilkinson CS; Wilkinson TC; Wilson FX
    Antivir Chem Chemother; 1999 Sep; 10(5):259-73. PubMed ID: 10574181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-throughput cell-based screening for hepatitis C virus NS3/4A protease inhibitors.
    Lee JC; Yu MC; Lien TW; Chang CF; Hsu JT
    Assay Drug Dev Technol; 2005 Aug; 3(4):385-92. PubMed ID: 16180993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Probing the active site of the hepatitis C virus serine protease by fluorescence resonance energy transfer.
    Fattori D; Urbani A; Brunetti M; Ingenito R; Pessi A; Prendergast K; Narjes F; Matassa VG; De Francesco R; Steinkühler C
    J Biol Chem; 2000 May; 275(20):15106-13. PubMed ID: 10809747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel azapeptide inhibitors of hepatitis C virus serine protease.
    Bailey MD; Halmos T; Goudreau N; Lescop E; Llinàs-Brunet M
    J Med Chem; 2004 Jul; 47(15):3788-99. PubMed ID: 15239657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blunting the Swiss army knife of hepatitis C virus: inhibitors of NS3/4A protease.
    White PW; Llinas-Brunet M; Bös M
    Prog Med Chem; 2006; 44():65-107. PubMed ID: 16697895
    [No Abstract]   [Full Text] [Related]  

  • 17. Structure-based design of inhibitors of NS3 serine protease of hepatitis C virus.
    Frecer V; Kabelác M; De Nardi P; Pricl S; Miertus S
    J Mol Graph Model; 2004 Jan; 22(3):209-20. PubMed ID: 14629979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural characterization of the interactions of optimized product inhibitors with the N-terminal proteinase domain of the hepatitis C virus (HCV) NS3 protein by NMR and modelling studies.
    Cicero DO; Barbato G; Koch U; Ingallinella P; Bianchi E; Nardi MC; Steinkühler C; Cortese R; Matassa V; De Francesco R; Pessi A; Bazzo R
    J Mol Biol; 1999 Jun; 289(2):385-96. PubMed ID: 10366512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibitors of hepatitis C virus NS3.4A protease 2. Warhead SAR and optimization.
    Perni RB; Pitlik J; Britt SD; Court JJ; Courtney LF; Deininger DD; Farmer LJ; Gates CA; Harbeson SL; Levin RB; Lin C; Lin K; Moon YC; Luong YP; O'Malley ET; Rao BG; Thomson JA; Tung RD; Van Drie JH; Wei Y
    Bioorg Med Chem Lett; 2004 Mar; 14(6):1441-6. PubMed ID: 15006379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis C virus NS3/4A protease.
    Kwong AD; Kim JL; Rao G; Lipovsek D; Raybuck SA
    Antiviral Res; 1999 Feb; 41(1):67-84. PubMed ID: 10321580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.